- ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3-targeting antibody-drug conjugate, in patients with advanced solid tumorWang, Jie; Duan, Jianchun; Xing, Ligang; Sun, Yuping; Guo, Wei; Wang, Haiying; Chen, Jianhua; Han, Liang; Liu, Baogang; Wang, Qiming; Hu, Ying; Wei, Hongying; Li, Chuan; Huang, Qiqi; Dong, Yiwei; Wu, QiongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 3
- First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumorsGong, Jifang; Zhang, Jian; Li, Ning; Shen, Lin; Wu, Lingying; Zhang, Youzhong; Huang, Yi; Wang, Ying; Wu, Junyan; Lou, Ge; Chen, Yaqing; Luo, Su-xia; Ba, Yi; Wang, Xian; Zheng, Yulong; Li, Guiling; Tong, Zhongsheng; Huang, Robert; Teng, Yan; Hu, XichunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumorsZhou, Q.; Wu, Y-L.; Li, J.; Liu, A.; Cui, J.; Kuboki, Y.; Yamamoto, N.; Han, S-W.; Lin, G.; Sun, J-M.; Wu, L.; Zhu, Z.; Shuang, J.; Qiu, F.; Shi, W.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors
8阅读
